Overview of Terlipressin Injection:

TERLINIS Injection contains Terlipressin. Terlipressin has affinity for both vasopressin V1 receptors. It is similar to a naturally occurring hormone present in the body, known as vasopressin. It causes narrowing of blood vessels (vasoconstriction), thereby limiting blood flow to a particular area of the body. It also acts on receptors in the kidney to retain water in the body, which helps to prevent excessive loss of water in the urine.

box-terlinis


Terlipressin is an analogue of Vasopressin abd belongs the class of Polypeptides.

TERLINIS Injection can be used in the treatment of following conditions:

  • Bleeding esophageal var ices
  • Type 1 hepatorenal syndrome, characterized by spontaneous acute renal insufficiency, in patients suffering form severe cirrhosis, with ascites.
    Management of low blood pressure


For bleeding esophageal varices: The initial recommended dose is 2 mg, then 1 or 2 mg 4-6 hourly until bleeding is controlled, up to 72 hour.
For hepatorenal syndrome: 1-2mg twice daily for 2-4 weeks.


Terlipressin is a vasoactive drug that acts on two different receptors, vasopressin receptor V1a (which initiates vasoconstriction, liver gluconeogenesis, platelet aggregation and release of factor VIII), vasopressin receptor V1b (which mediates corticotropin secretion from the pituitary).